FDA approves St. Jude Medical’s spinal cord stimulation therapy

St. Paul, Minn.-based St. Jude Medical earned Food and Drug Administration approval for its BurstDR stimulation technology, a physician-developed form of spinal cord stimulation used to treat patients with chronic pain.

Advertisement

Spinal cord stimulation uses an implant, placed near the spinal cord, to deliver mild electrical stimulation to the nerves along the spinal column to block pain messages from reaching the brain.

St. Jude’s BurstDR stimulation uses intermittent bursts of electrical pulses to copy the body’s natural nerve impulse patterns, according to the report.

Patients receiving stimulation implants from St. Jude will now have access to the new therapy and those already implanted with the devices will be able to upgrade their systems to administer BurstDR stimulation without additional surgery, the company said.

 

More articles on supply chain:

5 factors driving supply chain innovation
FDA approves Teva’s generic HIV drug
Hospital bed company LINET buys majority stake in BORCAD Medical

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.